Vimarsana
Biggest News Aggregation in the World

Page 2 - Failure Trial News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Failure Trial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Failure Trial Today - Breaking & Trending Today

BioCardia Announces Completion of Enrollment in Phase III CardiAMP HF Trial and Plans for CardiAMP HF Trial II - Vimarsana News

BioCardia Announces Completion of Enrollment in Phase III CardiAMP HF Trial and Plans for CardiAMP HF Trial II

SUNNYVALE, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for ...

BioCardia, Inc. (NASDAQ:BCDA) Q4 2022 Earnings Call Transcript - Vimarsana News

BioCardia, Inc. (NASDAQ:BCDA) Q4 2022 Earnings Call Transcript

Operator: Ladies and gentlemen, thank you for standing by. Good afternoon, and welcome to the BioCardia 2022 Yearend Conference Call. At this time, all participants are in a listen-only mode.

BioCardia, Inc. (BCDA) CEO Peter Altman on Q2 2022 Results - Earnings Call Transcript - Vimarsana News

BioCardia, Inc. (BCDA) CEO Peter Altman on Q2 2022 Results - Earnings Call Transcript

BioCardia, Inc. (NASDAQ:NASDAQ:BCDA) Q2 2022 Earnings Conference Call August 10, 2022, 04:30 PM ET Company Participants Jules Abraham - IR, CORE IR Peter Altman - President and CEO David...

BIOCARDIA : REPORTS SECOND QUARTER 2022 BUSINESS HIGHLIGHTS AND FINANCIAL RESULTS - Form 8-K - Vimarsana News

BIOCARDIA : REPORTS SECOND QUARTER 2022 BUSINESS HIGHLIGHTS AND FINANCIAL RESULTS - Form 8-K

BIOCARDIA REPORTS SECOND QUARTER 2022 BUSINESS HIGHLIGHTS AND FINANCIAL RESULTS Sunnyvale, Calif. - August 10, 2022 -BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and... | August 10, 2022

BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Study as Designed - Vimarsana News

BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Study as Designed

SUNNYVALE, Calif., Feb. 14, 2022 -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today... | February 14, 2022